Cost-effectiveness of janus kinase inhibitors for rheumatoid arthritis: A systematic review and meta-analysis of cost-utility studies

Cost-effectiveness of janus kinase inhibitors for rheumatoid arthritis: A systematic review and meta-analysis of cost-utility studies

Introduction: Janus kinase inhibitors (JAK-i), a class of targeted synthetic disease-modifying antirheumatic drugs (tDMARDs), are suggested as second or third-line therapies in rheumatoid arthritis (RA). Synthesized cost-effective evidence would aid in informed decision-making given the similar clin...

Full description

Bibliographic Details
Main Authors:	S. Sajith Kumar, Madhumitha Haridoss, Krishnamurthy Venkataraman, Bhavani Shankara Bagepally
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-12-01
Series:	Frontiers in Pharmacology
Subjects:	rheumatoid arthritis janus kinase inhibitors cost-effectiveness QALY evidence syntheses
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2022.1090361/full

Similar Items

RUSSIAN AND INTERNATIONAL EXPERIENCE IN THE APPLICATION OF THE JANUS-KINASES INHIBITOR IN RHEUMATOID ARTHRITIS
by: D. E. Karateev, et al.
Published: (2017-05-01)

Drug Retention Rates of Janus Kinase Inhibitors in Rheumatoid Arthritis Patients with Therapy-Induced Lymphopenia
by: Jumpei Temmoku, et al.
Published: (2023-07-01)

Drug survival and change of disease activity using a second janus kinase inhibitor in patients with difficult-to-treat rheumatoid arthritis who failed to a janus kinase inhibitor and subsequent biologics
by: Oh Chan Kwon, et al.
Published: (2024-04-01)

Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis
by: Przemysław J. Kotyla, et al.
Published: (2020-10-01)

Systematic Literature Review of Real-World Evidence on Baricitinib for the Treatment of Rheumatoid Arthritis
by: Blanca Hernández-Cruz, et al.
Published: (2023-09-01)

JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future
by: Jacopo Angelini, et al.
Published: (2020-07-01)

Novel Potential Janus Kinase Inhibitors with Therapeutic Prospects in Rheumatoid Arthritis Addressed by In Silico Studies
by: Andrei-Flavius Radu, et al.
Published: (2023-06-01)

BARICITINIB: NEW PHARMACOTHERAPY OPTIONS FOR RHEUMATOID ARTHRITIS AND OTHER IMMUNE-MEDIATED INFLAMMATORY RHEUMATIC DISEASES
by: E. L. Nasonov, et al.
Published: (2020-06-01)

Cardiovascular risk of Janus kinase inhibitors compared with biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis without underlying cardiovascular diseases: a nationwide cohort study
by: Yun-Kyoung Song, et al.
Published: (2023-10-01)

Household catastrophic health expenditures for rheumatoid arthritis: a single centre study from South India
by: Bhavani Shankara Bagepally, et al.
Published: (2023-09-01)

Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis
by: Martina Biggioggero, et al.
Published: (2019-10-01)

Venous Thromboembolism in Rheumatoid Arthritis: The Added Effect of Disease Activity to Traditional Risk Factors
by: Omair MA, et al.
Published: (2022-10-01)

Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE)
by: Hideto Kameda, et al.
Published: (2021-01-01)

Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases
by: Annie Mayence, et al.
Published: (2019-03-01)

Efficacy and safety of different Janus kinase inhibitors combined with methotrexate for the treatment of rheumatoid arthritis: a single-center randomized trial
by: Xiaoling Liao, et al.
Published: (2023-10-01)

Targeting of Janus Kinases Limits Pro-Inflammatory but Also Immunosuppressive Circuits in the Crosstalk between Synovial Fibroblasts and Lymphocytes
by: Nina Yao, et al.
Published: (2021-10-01)

Increased Levels of Omega-3 Fatty Acids and DHA Are Linked to Pain Reduction in Rheumatoid Arthritis Patients Treated with Janus Kinase Inhibitors
by: Ching-Kun Chang, et al.
Published: (2021-08-01)

Tofacitinib Decreases Autophagy of Fibroblast-Like Synoviocytes From Rheumatoid Arthritis Patients
by: M. Vomero, et al.
Published: (2022-03-01)

Upadacitinib for Patients with Rheumatoid Arthritis: A Comprehensive Review
by: Raimon Sanmartí, et al.
Published: (2023-02-01)

Janus kinase inhibitors vs. abatacept about safety and efficacy for patients with rheumatoid arthritis-associated interstitial lung disease: a retrospective nested case-control study
by: Atsuko Tsujii, et al.
Published: (2024-01-01)

Potential Adverse Events Reported With the Janus Kinase Inhibitors Approved for the Treatment of Rheumatoid Arthritis Using Spontaneous Reports and Online Patient Reviews
by: Yun-Kyoung Song, et al.
Published: (2022-01-01)

A case of aggressive squamous cell carcinoma with lymphovascular invasion during treatment with the Janus kinase inhibitor tofacitinib
by: Ahmad I. Aleisa, MD, et al.
Published: (2020-08-01)

Janus Kinases in Leukemia
by: Juuli Raivola, et al.
Published: (2021-02-01)

Baricitinib for the treatment of rheumatoid arthritis
by: Ivan Urits, et al.
Published: (2020-12-01)

Long-Term Retention Rate of Tofacitinib in Rheumatoid Arthritis: An Italian Multicenter Retrospective Cohort Study
by: Marino Paroli, et al.
Published: (2023-08-01)

Cervical lymphadenitis caused by Mycobacterium avium in a patient treated with Janus kinase inhibitors
by: Wataru Fujii, et al.
Published: (2023-08-01)

MODERN PRINCIPLES OF MANAGEMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS
by: D. E. Karateev, et al.
Published: (2017-11-01)

Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data
by: Hong Ki Min, et al.
Published: (2023-04-01)

More Unnecessary Imaginary Worlds - Part 1: The Institute for Clinical and Economic Review’s Evidence Report on Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
by: Paul Langley
Published: (2020-01-01)

Successful Treatment of a Patient with Drug-Refractory Rheumatoid Arthritis-Associated Interstitial Lung Disease with Upadacitinib: A Case Report
by: Yuuya Nishii, et al.
Published: (2023-11-01)

Management of Rheumatoid Arthritis: An Overview
by: Andrei-Flavius Radu, et al.
Published: (2021-10-01)

Comparative efficacy and safety of JAK inhibitors as monotherapy and in combination with methotrexate in patients with active rheumatoid arthritis: A systematic review and meta-analysis
by: Li Liu, et al.
Published: (2022-09-01)

Janus kinase inhibitors: between prescription authorization and reimbursability
by: F.R. Spinelli, et al.
Published: (2023-12-01)

Tofacitinib and Baricitinib in Type 2 Diabetic Patients with Rheumatoid Arthritis
by: Cristina Martinez-Molina, et al.
Published: (2024-02-01)

Upadacitinib as Novel Treatment for Rheumatoid Arthritis with T-Cell Granular Lymphocytic Leukemia: A Case Report and Narrative Review
by: Young Min Cho, et al.
Published: (2022-07-01)

Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib
by: Robert Harrington, et al.
Published: (2023-10-01)

Role of Janus Kinase Inhibitors in Therapy of Psoriasis
by: Sylwia Słuczanowska-Głąbowska, et al.
Published: (2021-09-01)

Janus Kinase inhibitors in dermatology: a review
by: Bárbara Vieira-Granja, et al.
Published: (2023-01-01)

Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study
by: Mark C. Genovese, et al.
Published: (2019-08-01)

Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: Final Results from the BALANCE-EXTEND Open-Label Extension Study
by: Alan Kivitz, et al.
Published: (2023-05-01)